ARID1A and cancer: Notably, the identification of ARID1A and p16 as key relapse predictors aligns with prior studies linking these biomarkers to aggressive EC phenotypes [39], [48] and aligns with emerging biomarker-driven ML frameworks in cancer research [3], [46], [76]